A study to evaluate the dose-response effect of tolvaptan 7.5mg or 15mg in HF patients who undergo cartdiac angiography
Not Applicable
- Conditions
- Heart Failure
- Registration Number
- JPRN-UMIN000009924
- Lead Sponsor
- Showa University Northern Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1)history of allergy against this drug or similar compounds (2)anuria (urine volume <100ml/day) (3)subjects who cannot feel thirsty or have difficulty to drink (4)subjects whose serum sodium level is over 147mEq/L (5)subjects who are pregnant or possibly pregnant (6)subjects who already have tolvaptan at the entry (7)acute coronary syndrome (8)patients who are judged to be inappropriate to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of contrast-induced nephropathy within 48 hours after the administration of radiocontrast agents
- Secondary Outcome Measures
Name Time Method (1)Renal injury at 48h after the procedure (Percent changes of serum creatinine /CysC/BNP/urinary albumin) (2) Major post-procedure in-hospital adverse clinical events, including cardiogenic shock, clinically significant arrhythmia, CIN requiring renal replacement therapy (hemofiltration or homodiafiltration), pulmonary edema, and death